Advanced Pancreatic Cancer: Expert Perspectives on Treatment and Emerging Therapies
Advanced Pancreatic Cancer: Expert Perspectives on Treatment and Emerging Therapies
Release Date: June 24, 2020
Last Reviewed: June 15, 2020
Expiration Date: June 24, 2021
Time to Complete Activity: 1.0 hours
*This activity expired for credit on June 24, 2021 and is no longer available for credit
Faculty
Steering Committee
Eileen M. O’Reilly, MD
Winthrop Rockefeller Chair in Medical Oncology
Section Head, Hepatopancreaticobiliary and Neuroendocrine Cancers
Associate Director, David M. Rubenstein Center for Pancreatic Cancer Research
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, NY
Zev A. Wainberg, MD
Associate Professor of Medicine and Surgery
Co-Director, GI Oncology
Director, Early Phase Clinical Research Program
Jonsson Comprehensive Cancer Center
David Geffen School of Medicine at UCLA
Los Angeles, CA
Contributing Faculty
Christopher H. Crane, MD
Vice Chairman and Attending
Memorial Sloan Kettering Cancer Center
New York, NY
Mark Schattner, MD, FASGE, AGAF
Chief, Gastroenterology, Nutrition, and Hepatology Service
Memorial Sloan Kettering Cancer Center
Professor of Clinical Medicine
Weil Cornell College of Medicine
New York, NY
Alice C. Wei, MD, MSc
Associate Attending Surgeon
Hepatopancreatobiliary Service
Department of Surgery
Memorial Sloan Kettering Cancer Center
New York, NY
This activity is provided by Paradigm Medical Communications, LLC.
Target Audience
This activity has been designed to address the educational needs of oncology physicians and advanced practitioners practicing in community and academic settings. It will also be of benefit to oncology nurses, pathologists, interventional radiologists, residents, fellows, and other clinicians who treat patients with pancreatic cancer.
Learning Objectives
Upon proper completion of this activity, participants should be better able to:
- Incorporate guideline-recommended diagnostic and pathologic tests for patients with metastatic pancreatic cancer
- Apply the latest clinical trial data and current guidelines to optimally select treatment for patients with metastatic pancreatic cancer
- Review the latest data for emerging treatments of metastatic pancreatic cancer, and the potential benefits for patients enrolled in trials of these therapies
- Introduction
- Guideline-Recommended Treatment of Advanced Pancreatic Cancer
- Emerging Regimens for Advanced Pancreatic Cancer
- Conclusions and Q&A
Paradigm Medical Communications, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physician Credit Designation Statement
Paradigm Medical Communications, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PA Continuing Education
PAs may claim a maximum of 1.0 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
This activity is supported by educational grants from Celgene Corporation, Erytech, and Ipsen Biopharmaceuticals, Inc.
Instructions for Participation
To receive a CME certificate of participation, you should:
- Follow instructions to register or log in with your professional information and complete the pre-activity assessment
- View the online activity in its entirety
- Complete and submit the online posttest and evaluation. You must answer 70% of the posttest questions correctly to earn credit. You will have unlimited opportunities to successfully complete the posttest
For questions regarding CME credit, contact the Paradigm CME Department at (845) 398-5949.
There is no fee required for participation in this activity.
Hardware/Software Requirements
This certified CME activity is designed using HTML5 web components. As you navigate the video using the supplied controls, the slides will sync to the speaker.
Supported Browsers (Desktop/Mobile)
Chrome 45+, Firefox 40+, Edge, Edge Chromium, Safari 8+, Opera 31+
PDF documents
This activity may contain PDF documents. Most current browsers support viewing of PDFs natively, but you may also download a free version of Adobe Acrobat Reader here: http://get.adobe.com/reader.
Technical Support: If you have any technical problems or playback issues email us at contactus@paradigmmc.com.
Disclosures
In accordance with ACCME requirements on disclosure, faculty and contributors are asked to disclose any relationships with commercial interests associated with the area of medicine featured in the activity. These relationships are described below.
Steering Committee
Eileen M. O’Reilly, MD
Grant/Research Support (Self): ActaBiologica; Agios, Inc; Array BioPharma; AstraZeneca, Bayer HealthCare; BeiGene;
Bristol-Myers Squibb Company; Casi Pharmaceuticals Inc; Celgene Corporation; Exelixis, Inc; Genentech, Inc; Mabvax Therapeutics, Inc; Novartis Pharmaceuticals Corporation; Polaris Pharmaceuticals; Puma Biotechnology, Inc;
QED Therapeutics; Roche
Grant/Research Support (Spouse): ActaBiologica; Agios, Inc; Array BioPharma; AstraZeneca, Bayer HealthCare; BeiGene;
Bristol-Myers Squibb Company; Casi Pharmaceuticals Inc; Celgene Corporation; Exelixis, Inc; Genentech, Inc; Mabvax Therapeutics, Inc; Novartis Pharmaceuticals Corporation; Polaris Pharmaceuticals; Puma Biotechnology, Inc;
QED Therapeutics; Roche
Retained Consultant (Self): AstraZeneca, Celgene Corporation; CytomX Therapeutics, Inc; Ipsen Biopharmaceuticals, Inc; Merck & Co, Inc; Pfizer Inc; Polaris Pharmaceuticals; Silenseed LTD; Sobi; Targovax
Retained Consultant (Spouse): Agios, Inc; AstraZeneca, Bayer HealthCare; BeiGene; Bristol-Myers Squibb Company; Celgene Corporation; Debiopharm Group; Eisai; Eli Lilly and Company; Exelixis, Inc; Flatiron; Genoscience Pharma; Incyte; Ipsen Biopharmaceuticals, Inc; LAM Inc; Merck & Co, Inc; MINAPHARM Pharmaceuticals; QED Therapeutics; Redhill;
sanofi-aventis US LLC; SillaJen, Inc; Vicus Therapeutics, LLC; Yiviva
Zev Wainberg, MD
Grant/Research Support: Bristol-Myers Squibb Company; Eli Lilly and Company; Ipsen Biopharmaceuticals, Inc;
Merck & Co, Inc; Novartis Pharmaceuticals Corporation
Retained Consultant: Bayer HealthCare; Eli Lilly and Company; Ipsen Biopharmaceuticals, Inc; Merck & Co, Inc
Contributing Faculty
Christopher H. Crane, MD
No financial relationships to disclose.
Mark Schattner, MD, FASGE, AGAF
Retained Consultant: Boston Scientific
Alice C. Wei, MD, MSc
Other (Travel Fees): Bayer Pharmaceuticals; Intuitive Pharma
Paradigm Medical Communications, LLC staff members have no financial relationships to disclose.
Independent peer, resident/fellow and patient reviewers has no financial relationships to disclose.
Resolution of Conflict of Interest
Paradigm Medical Communications, LLC has implemented a system to resolve conflicts of interest for each CME activity to help ensure content is objective, fair and balanced, independent, and aligned with the public interest. Conflicts, if any, are resolved through one or more processes. All CME content in this activity was independently reviewed to ensure that it is free of commercial bias, scientifically rigorous, aligned with the public interest, and compliant with all regulatory guidance and the ACCME’s Standards for Commercial Support of Continuing Medical Education.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not approved by the FDA.
Disclaimer
This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. Reasonable efforts have been taken to present educational subject matter in a balanced, unbiased fashion, and in compliance with regulatory requirements. However, each activity participant must always use his or her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
If included, signed statements of informed consent granting permission for publication have been obtained for all photographs and videos in which an individual can be identified.
As an ACCME-accredited provider, Paradigm Medical Communications, LLC activities must include a balanced view of therapeutic options. Use of generic names contributes to this impartiality. The use of trade names should not be viewed as an endorsement of specific products by Paradigm Medical Communications, LLC.
Terms of Use and Privacy Policy
Disclaimer
The materials provided for this activity are for informational purposes only, and should not be used for diagnosis or treatment of a health problem without consulting a licensed medical professional. This CME activity represents the views and opinions of the individual faculty, and does not constitute the opinion or endorsement of, or promotion by, Paradigm Medical Communications, LLC. References to any entity, product, service, or source of information on this website should not be considered an endorsement, either direct or implied, by Paradigm Medical Communications, LLC. Paradigm Medical Communications, LLC, accepts no liability for the content referenced in this activity.
Privacy policy
Paradigm Medical Communications, LLC or hosted contracted partner is committed to protecting the privacy of those who participate in the activities located at www.paradigmmc.com (herein referred to as “website"). The information below describes the security of the website for safeguarding personal information and the rationale for collection and use of personal information.
Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.
Collection and use of your personal information
The submission of certain personally identifiable information is necessary to award and track the credits participants may earn after completing the program. Required items include first name, last name, degree, and email address. These items are necessary. Participants are also required to complete an evaluation of the CME activity. All evaluative information submitted is collected and retained, and used by Paradigm Medical Communications, LLC to continuously improve the learning experience.
Paradigm Medical Communications, LLC does not transfer, sell, or share personal information with outside parties. Paradigm Medical Communications, LLC will not otherwise disclose personal information unless required to in a legal process. Paradigm Medical Communications, LLC staff members review individual test results to the extent necessary to record and track participants’ credits.
Contact Us
If you have any questions or comments, please email us at contactus@paradigmmc.com.
© 2020 Paradigm Medical Communications, LLC except where noted. Content may not be reproduced in whole or part without the express written permission of Paradigm Medical Communications, LLC.